• This oversold ASX gold developer could more than double: Broker

    Man putting golden coins on a board, representing multiple streams of income.

    Minerals 260 Ltd (ASX: MI6) this week released the results of a prefeasibility study into its Bullabulling gold project in Western Australia, and it’s fair to say the market was underwhelmed.

    While the stock is up more than 440% over the past 12 months, the shares dipped slightly on the publication of the PFS and are now trading at 62 cents.

    The analysts at Morgans believe this is cheap and have a bullish share price target on the gold company’s shares, which we’ll get to later.

    First, let’s look at what they announced.

    Major, long-life gold project in development

    The company said in a statement to the ASX that Bullabulling would generate average annual free cash flow of $330 million and would operate for 19 years.

    The company would spend $180 million from existing cash reserves to get to a final investment decision, while the mine would cost $560 million to build, plus another $115 million for pre-production operations.

    A definitive feasibility study was expected to be completed in the first quarter of calendar year 2027.

    Minerals 260 Managing Director Luke McFadyen said regarding the project:

    Fifteen months after acquiring the Bullabulling Gold Project, we are presenting outcomes of our PFS and a Maiden Ore Reserve. We always believed Bullabulling could become a significant gold operation, and today’s outcomes confirm the potential for this high-margin, large-scale, long-life Project. Our target of delivering Bullabulling into production by the end of 2028 will establish Minerals 260 as the next mid-tier gold producer on the ASX. With an NPV of $2.3 billion, an IRR of 43% and $510M of average annual EBITDA, Bullabulling is set to deliver significant growth and value for our shareholders.

    Shares in this ASX gold company looking cheap

    Morgans said, importantly, that the PFS was completed using the previous 4.5 million-ounce gold resource, with an upgraded 6.2 million-ounce resource providing scope for further resource growth.

    They added:

    The market has reacted negatively to the PFS, which we believe is largely a product of the crystallisation of a sizeable upfront capital requirement rather than any deterioration in project quality. While pre-production capital of ~A$855m is significant, we view it as appropriate for an asset of Bullabulling’s scale, longevity and economic returns, with the project’s strong cash-generative profile expected to support favourable financing outcomes.

    Morgans is anticipating first production in mid FY29 with an average output of about 150,000 ounces per year initially.

    They added:

    We assume a Stage 2 expansion, funded from operating cash flow, is commissioned in 2H FY31, increasing production towards ~200kozpa. Beyond lifting the production profile, the larger-scale operation has the potential to benefit from economies of scale and lower unit operating costs, although we do not currently incorporate these benefits into our base case.

    Morgans has a price target of $1.38 on Minerals 260 shares.

    The post This oversold ASX gold developer could more than double: Broker appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Minerals 260 right now?

    Before you buy Minerals 260 shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Minerals 260 wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 16 June 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • 9 ASX 200 shares with reiterated buy calls this week

    Green keyboard button saying buy stock.

    S&P/ASX 200 Index (ASX: XJO) shares are 0.5% higher on Friday at 8,801.8 points.

    Brokers have indicated continuing confidence in several ASX 200 shares this week.

    Let’s take a look.

    Telstra Group Ltd (ASX: TLS)

    The Telstra share price is $4.99, up 0.1% today and up 2.2% over 12 months.

    Morgan Stanley reiterated its buy rating on Telstra shares on Wednesday.

    The broker lowered its 12-month share price target from $5.40 to $5.30.

    This implies potential capital gains of 6% in FY27.

    Liontown Ltd (ASX: LTR)

    The Liontown share price is $1.47, down 0.5% today and up 83% over 12 months.

    The lithium producer was one of the 5 top ASX 200 mining shares for capital growth in FY26.

    Macquarie renewed its buy rating on Liontown shares with a $2.30 target this week.

    This suggests a potential 57% upside ahead.

    Life360 Inc (ASX: 360)

    The Life360 share price is $25.82, down 0.4% today and down 21% over 12 months.

    Citi reiterated its buy rating on Life360 shares on Tuesday.

    The broker raised its target from $28.25 to $31.95.

    This implies potential capital gains of 24% ahead.

    Pro Medicus Ltd (ASX: PME)

    The Pro Medicus share price is $199.48, down 5.1% today and down 37% over 12 months.

    However, that 12-month performance belies this ASX 200 healthcare share’s incredible comeback in CY26.

    Pro Medicus shares hit a 52-week low of $107.75 on 24 February. Since then, they’ve ripped 85% higher.

    And since the broader healthcare sector pivoted on 3 June, Pro Medicus shares have outperformed with a 25% gain.

    That compares to a 21% increase in the S&P/ASX 200 Health Care Index (ASX: XHJ) since 3 June.

    Citi sees more room for growth, and reiterated its buy rating with a $240 target this week.

    This suggests another 20% upside ahead.

    South32 Ltd (ASX: S32)

    The South32 share price is $4.02, up 5.2% today and up 32% over 12 months.

    Morgan Stanley maintained its buy rating on the ASX 200 mining share this week.

    The broker shaved its 12-month target down from $4.85 to $4.75.

    This implies a potential 18% upside ahead.

    BHP Group Ltd (ASX: BHP)

    The BHP share price is $58.28, up 2.5% today and up 52% over 12 months.

    Morgan Stanley renewed its buy rating on BHP shares with a $67.50 target this week.

    This suggests a potential 15% upside in the new financial year.

    WiseTech Global Ltd (ASX: WTC)

    The WiseTech share price is $34.24, down 1.1% today and down 70% over 12 months.

    This tech share was the fastest faller of the ASX 200 in FY26.

    Citi anticipates a strong recovery for WiseTech shares and renewed its buy rating this week.

    However, the broker cut its 12-month target significantly from $65.65 to $52.

    This still implies potential capital gains of 52% in FY27.

    Paladin Energy Ltd (ASX: PDN)

    The Paladin Energy share price is $10.15, up 5.1% today and up 46% over 12 months.

    Morgan Stanley kept its buy call on the ASX 200 energy share but lowered its target from $13.65 to $11.95 this week.

    This suggests a potential 17% upside ahead.

    Coles Group Ltd (ASX: COL)

    The Coles share price is $23.58, down 0.4% today and up 15% over 12 months.

    UBS renewed its buy rating on the ASX 200 consumer staples share with a $25.50 target on Monday.

    This suggests a potential 8% upside ahead.

    The post 9 ASX 200 shares with reiterated buy calls this week appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Life360 right now?

    Before you buy Life360 shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Life360 wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 16 June 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor Bronwyn Allen has positions in BHP Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360, Macquarie Group, and WiseTech Global. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Life360, Telstra Group, and WiseTech Global. The Motley Fool Australia has recommended BHP Group, Macquarie Group, and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • How high does Macquarie think this ASX drone technology company will go?

    A silhouette of a soldier flying a drone at sunset.

    Most investors wouldn’t think of drones initially when thinking of Codan Ltd (ASX: CDA), with the company having traditionally based its business around radio communications technology and metal detector sales.

    But the company’s DTC division, which it acquired back in 2021, has developed radio technology for use on drone platforms, which has piqued the interest of the analysts at Macquarie.

    Major opportunity for ASX drone players

    The Macquarie team said in a recent note to clients that there is expected to be exponential growth in drone spending, citing a recent NATO initiative called “drone edge”, which envisages US$40 billion worth of investment in the sector from more than 30 countries.

    They added:

    As we mentioned in a previous report, the US Department of War’s 2027 budget overview includes US$53.6bn in funding for drone and autonomous systems and US$21bn for counter drone technologies. This dedicated investment into autonomous systems’ procurement, domestic production capacity and advanced capabilities is being divided across multiple specialised programs.

    They said in relation to Codan:

    When encompassing estimated communication layer drone costs and US-specific programs, together these frame a large, multi-year, structurally growing US demand pool that plays directly to DTC’s niche. DTC’s key offering of resilient datalink, mesh-networking and electronic warfare hardened communications layer is directly linked to various components that multi-domain drone and unmanned systems require.

    The Macquarie team said beyond the US, “DTC also has significant opportunities in the European region as noted by management back at the 1H26 result”.

    They added:

    Europe has emerged as a structurally attractive opportunity as the recent step-change in defence spending driven by the war in Ukraine and NATO eastern-flank deterrence is flowing into unmanned-systems and resilient communications categories where DTC competes.

    Macquarie said the Asia-Pacific region was also shaping up as one of the most compelling regions for DTC, driven by a surge in defence spending.

    Australia itself was a “high-conviction oppoprtunity”, with the company’s radios already selected for the Land 129 UAV project.

    Macquarie added regarding the company:

    To meet surging international demand for secure communications solutions as a part of the increasing demand for drones and uncrewed systems, DTC has established a multi-country manufacturing footprint, expanding production outside the US. The newer established manufacturing locations for DTC, the United Kingdom and Australia, help to de-risk global supply chains. This expansion in manufacturing positions DTC well to capture opportunities across different regions globally.

    Shares looking cheap

    Macquarie has a price target of $48.50 on Codan shares compared with $43.25 currently.

    The company is valued at $8.09 billion.

    The post How high does Macquarie think this ASX drone technology company will go? appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Codan right now?

    Before you buy Codan shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Codan wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 16 June 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.